-
Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.
Dec 7, 2023
-
Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.
Dec 5, 2023
-
Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.
Nov 30, 2023
-
Diagnostics World | Illumina enters a multi-year agreement with Veracyte to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument; Boston Scientific Corporation acquires Relievant Medsystems to add to chronic pain portfolio; Oxford Nanopore Technologies and Fabric Genomics collaborate to develop a software solution analysis and clinical reporting of rich genomic data for faster insights to support rapid disease characterization of babies and children with genetic disorders in acute settings; more.
Nov 29, 2023